Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Leases (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Current Leases for 7 consecutive years, with $14.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 6.64% to $14.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.4 million, a 6.64% increase, with the full-year FY2025 number at $14.4 million, up 6.64% from a year prior.
  • Current Leases was $14.4 million for Q4 2025 at Beam Therapeutics, up from $12.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $14.4 million in Q4 2025 to a low of $912000.0 in Q2 2023.
  • A 5-year average of $9.0 million and a median of $10.8 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: plummeted 90.41% in 2023, then skyrocketed 1286.07% in 2024.
  • Beam Therapeutics' Current Leases stood at $2.3 million in 2021, then surged by 353.87% to $10.4 million in 2022, then increased by 23.1% to $12.8 million in 2023, then increased by 5.41% to $13.5 million in 2024, then grew by 6.64% to $14.4 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Current Leases are $14.4 million (Q4 2025), $12.7 million (Q3 2025), and $12.9 million (Q2 2025).